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(88.9%) restarted treatment. CONCLUSION Only little of the therapeutic effect of anti-calcitonin gene-
related peptide antibodies outlasts their pharmacological effect. After treatment interruption, migraine
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Abstract
Objective: This study aims to analyse the effect of the discontinuation of anti-calcitonin gene-related peptide antibodies
on monthly migraine days after 12 treatment months.
Background: Anti-calcitonin gene-related peptide antibodies have been a game changer in migraine prophylaxis.
However, high treatment costs warrant reducing treatment duration to the essential minimum.
Methods: We collected data of patients with migraine who had received anti-calcitonin gene-related peptide antibodies
and had received treatment for 12 months.
Results: We included 52 patients. The average number of monthly migraine days was 16 7 days at baseline, 6 6 in
the third, and 5 4 in the 12th treatment month. After treatment interruption, the number of monthly migraine days
was 6 4 days in the first month, 9 4 days in the second, and 11 5 days in the third month. Most patients (88.9%)
restarted treatment.
Conclusion: Only little of the therapeutic effect of anti-calcitonin gene-related peptide antibodies outlasts their phar-
macological effect. After treatment interruption, migraine frequency rose in most patients, and prophylaxis was required
again in most cases.
Limiting treatment to benefitting patients and confirming the need for prophylaxis periodically is reasonable. However,
our data does not support the need for prescheduled treatment discontinuation after 12 months and a fixed duration of
the treatment interruption of 3 months.
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CGRP¼ calcitonin gene-related peptide
MMD¼monthly migraine days
Introduction
Monoclonal antibodies targeted against calcitonin
gene-related peptide (CGRP) or its receptors have
been a game changer in migraine treatment. For the
first time, a drug was developed explicitly for migraine
prevention (1). Growing numbers of prescriptions doc-
ument the success of these medications and hint at
migraineurs’ unmet needs (2).
So far, available safety data have not raised con-
cerns against long-term therapy (3–6). However,
given the high treatment costs, a limitation of the treat-
ment duration to the essential minimum is desirable.
Besides, given the fluctuations of the attack frequency
during migraineurs’ lives (7), eventually, prophylactic
treatment might not be necessary any longer.
Accordingly, guidelines generally suggest re-
evaluating the need for migraine prophylaxis after 6–
12 months (8,9).
Deciding about treatment interruption would be
facilitated if the consequences were predictable. In par-
ticular, there are two urgent questions. First, how does
treatment cessation influence the attack frequency?
Second, is there a minimum period necessary to
decide whether a patient requires treatment again?
Swiss reimbursement rules have created a unique situ-
ation that allows answering these questions under real-
life conditions.
First, only neurologists can prescribe anti-CGRP
antibodies, with erenumab, galcanezumab, and frema-
nezumab currently being available (10). Second, treat-
ment with at least two drugs licenced for migraine
prophylaxis – that is, beta-blockers, calcium antago-
nists, or anticonvulsants (10) – must have been ineffec-
tive, contraindicated or not tolerated. Third, the mean
number of monthly migraine days (MMD) in three
consecutive months must be at least eight before the
prescription can be made.
Patients taking erenumab are allowed to increase the
dose after 3 months from 70 to 140 mg if the number of
MMD did not drop by at least 50%. Treatment must
be discontinued after 6 months if the MMD were not
reduced by at least 50%. It must be halted in any case
after 12 months and may be resumed 3 months later if
the MMD rose to eight or more again (11). Exceptions
from these rules are possible but need to be negotiated
individually with insurance companies unless patients
bear treatment costs themselves.
This study aimed to analyse the effects of the dis-
continuation of anti-CGRP antibodies on MMD after
12 successful treatment months.
Methods
Study design and data collection
Participating neurologists and headache experts from
five study centres sent the fully anonymised data to one
of the authors (HP) who conducted the statistical anal-
ysis. HP and CJS did not provide patient data. Data
collection started in October 2020 and ended in
December 2020. Inclusion criteria were a migraine
diagnosis (episodic and chronic), and treatment with
monthly injections of a monoclonal CGRP antibody
for 12 months. We excluded patients if the provided
data were obviously faulty. We included each centre’s
first consecutive patients who met the inclusion criteria.
The sample size was based on the available data.
We collected the following information: Age, sex,
headache diagnoses, name of the prescribed antibody,
MMD in the 3 months preceding the treatment (base-
line), at 3 months and 12 months of treatment, and in
the first, second, and third month after treatment ces-
sation, as well as in the first month after treatment
restart. Furthermore, we assessed adverse events and
the reasons not to restart treatment after the interrup-
tion (if applicable). To limit the risk of a reporting bias,
we asked neurologists to contribute data of their first
patients treated with anti-CGRP antibodies.
No formal approval of an ethics committee was nec-
essary, because neurologists provided strictly anony-
mised and routinely collected data of their patients
and because the person undertaking the statistical anal-
ysis was unaware of their identity. Therefore, this study
did not fall under the Human Research Act (12) and
obtained a waiver from the concerned ethics commit-
tees (Req-2020-01324).
Statistical analysis
We describe continuous variables as means, standard
deviations, and ranges, proportions as percentages and
categorical variables as frequencies. Missing values are
referred to as not reported (nr).
Also, we determine the lowest possible number of
migraine days in the first and second month after the
interruption, predicting that a patient will have eight or
more migraine days in the third month and
therefore qualify for treatment with anti-CGRP anti-
bodies again.




The data collected and analysed for the current study
are available from the corresponding author on reason-
able request.
Results
We received data from 52 patients (47 females; 90.4%)
with an average age of 48 12 years (range 19–74
years). No data had to be excluded. Of these, 21 suf-
fered from chronic migraine, 26 from episodic migraine
without aura, two from episodic migraine with aura,
and three from episodic migraine with and without
aura. Besides, four (4/52, 7.7%) had received the diag-
nosis “medication overuse headache” at baseline.
Patients took erenumab (51/52; 98.1%) – in the 12th
treatment month, 24 received doses of 70 mg, and 27 of
140 mg – or galcanezumab (1/52, 1.9%).
Most patients experienced no adverse events (41/52,
78.8%); seven (7/52, 13.5%) reported constipation, two
patients (2/52, 3.8%) complained about muscle cramps,
one patient (1/52, 1.9%) about itching, one about flu-
like symptoms, and one about an increase in headache
days during the first 2 weeks after the first injection.
During the 3 months preceding the first injection
(baseline), there were, on average, 16 7 MMD
(range 6–30). Furthermore, there were 6 6 MMD
(range 0–28; 1 nr) after three, and 5 4 MMD (range
1–20; 1 nr) after 12 treatment months. Within the first
year, the average reduction in MMD was 11 6 days
(range 2–29; 1 nr), and the average percentage reduc-
tion was 68.9% (SD 20.3, range 23.5–96.7%).
After 12 months, 45 patients (45/52, 86.5%) inter-
rupted treatment with anti-CGRP antibodies. Of them,
40 (40/42, 88.9%, 3 nr) restarted treatment, averagely
after 13 3 weeks (range 8–20, 8 nr). The reasons not
to restart were the patient’s subjective feeling of lacking
efficacy and in another case, the patient’s impression
that after having changed the workplace, a migraine
prophylaxis might not be necessary anymore.
In eight patients, it was unknown when treatment
was restarted; six patients already picked up treatment
after 2 months (6/32, 18.8%, 8 nr). Consequently, in
the first and second month after treatment interrup-
tion, 34 patients, and 28 in the third month had not
restarted treatment yet. Among them, the number of
MMD was 6 4 days (range 0–15 days) in the first
month, 9 4 days (range 2–19 days) in the second
month, and 12 5 days (range 1–21 days) in the third
month. Among those who had interrupted treatment
for at least 3 months, the number of MMD was 6 4
days (range 2–15 days) in the first month after treat-
ment was started again.
Compared with the 12th treatment month, the
MMD increased in 18 of 34 patients (52.9%) in the
first month, and in 30 of 34 patients (88.2%) in
the second month after treatment cessation. In the
third month, six patients restarted treatment and
MMD increased in 25 of the remaining 28 patients
(89.3%) compared with the last month on treatment.
In the third month without treatment, MMD were
as high as or higher than at baseline in seven patients
(7/28; 25.0%); 24 of 28 patients (85.7%) had eight or
more MMD and, thus, qualified for treatment with
CGRP antagonists. Compared to baseline, MMD in
the third month dropped by 25% (SD 49.7, range
163–97.0%) on average.
In the first month after the interruption, the lowest
cut-off value predicting that a patient would have eight
or more MMD in the third month, which resulted in
zero false positives, was eight MMD; sensitivity was
0.190 because 17 of 21 were false negatives.
In the second month of the treatment interruption,
the best cut-off value was 10, with zero false positives,
and a sensitivity of 0.222 (14 of 18 were false negatives).
Applying a cut-off value of eight would result in one
false and 14 true positives (specificity 0.933), as well as
14 false and four true negatives (sensitivity 0.222).
Of all patients who had interrupted treatment for at
least 3 months and had eight or more MMD in the
third month, more than half had already had at least
8 days in the preceding months (14/24, 58%, 4 nr).
Table 1 summarises differences in MMD between
patient with episodic and chronic migraine.
Discussion
In this study, we analysed the MMD following discon-
tinuation of anti-CGRP antibodies after 12 months of
therapy. Treatment interruption resulted in an increase
in MMD in almost all patients within 3 months. Half
of them reached a migraine frequency that was as high
as or higher than at baseline. Nevertheless, the MMD
were, on average, still reduced by 25% in the third
month after the last dose.
Reimbursement authorities insist on an interruption,
probably attempting to reduce costs and avoid unnec-
essary treatment, especially since long-term data were
initially lacking. However, our data show that all
patients are at risk of relapsing into high numbers of
MMD. Given the tremendous impact of frequent
migraine attacks on migraineurs’ lives (13,14), it is a
medical, social and economic imperative to prioritise
preventing the migraine frequency from rising again.
Hence, the interruption should be as short as possible.
According to Swiss governmental bodies, patients
with at least eight or more migraine days in the third
month after the last injection may resume treatment
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(11). Our data indicate that it is often unnecessary to
wait 3 months for patients to meet these criteria. The
ictal burden continues to increase after treatment ces-
sation, and almost all patients who reach the threshold
of eight migraine days in the first or the second month
will have eight or more migraine days in the third
month, too. Therefore, we suggest not postponing
treatment restart when the number of MMD has
reached the threshold value again.
Interestingly, despite differing baseline values, the
number of MMD dropped to similar values in patients
with episodic and chronic migraine (see Table 1),
implying a greater reduction in MMD in chronic
migraine. This finding is in line with previous studies
suggesting that erenumab leads to a greater reduction
in the number of migraine days in chronic migraine
(3,15,16). After the interruption, MMD rose somewhat
more slowly in chronic migraine. Consequently, it is
possible that CGRP in the peripheral nervous systems
is more relevant in the pathophysiology of chronic than
episodic migraine.
An important question is whether treatment inter-
ruption after 12 months is justified in migraine patients
at all. Since most patients in this study restarted the
therapy, an interruption after 12 months could be too
early. It is unlikely that the cost saved by the treatment
discontinuation outweighs the increased disease burden
the patients had to bear, especially given that the treat-
ment was very well tolerated. We encourage studies
investigating changes in the disease burden
prospectively.
In accordance with a recent study (17), our data
show that migraine frequency generally rises quickly
after treatment interruption (see Figure 1). This finding
Table 1. Differences between patients with episodic an chronic migraine; MMD – monthly migraine days.
Episodic migraine Chronic migraine
MMD at baseline 14 7 (n¼ 31) 20 5 (n¼ 21)
MMD after 3 treatment months 6 5 (n¼ 31) 7 6 (n¼ 20)
MMD after 12 treatment months 5 4 (n¼ 31) 5 4 (n¼ 20)
MMD during the first month after treatment interruption 8 4 (n¼ 19) 5 3 (n¼ 15)
MMD during the second month after treatment interruption 9 5 (n¼ 19) 8 4 (n¼ 15)
MMD during the third month after treatment interruption 12 6 (n¼ 14) 11 4 (n¼ 14)
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Figure 1. Monthly migraine days at different time points.
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suggests that most of the therapeutic effect does not
outlast the pharmacological effect. However, about
half of the patients did not reach their baseline
number of MMD after 3 months. Given the half-life
of about 28 days (18), plasma concentration has
dropped by seven eighths in the third month after dis-
continuation. Consequently, it is unlikely that the last-
ing effect is due to the small proportion of the drug
remaining in the body.
There may be several reasons for the persisting treat-
ment effect. First, any medication overuse headache
present at baseline probably would have resolved
after 12 months in most 50% responders. Second,
high numbers of MMD at baseline might have contrib-
uted to an increased attack frequency; for example,
through central sensitisation. Third, lower attack fre-
quencies during the treatment period might have
relieved stress that many patients recall as a migraine
trigger (19). Finally, even a disease modification effect
could be speculated.
Strengths and limitations
Because of the requirements for the reimbursement of
anti-CGRP antibodies (11), we can assume that
migraine diagnosis was correct, and there was accurate
documentation of MMD in the diaries. Besides, after
12 months, plasma concentration had reached a steady
state. Hence, all patients had halted treatment under
similar conditions and study results were generalisable.
A limitation is that we had asked participating neu-
rologists to report their first patients treated with anti-
CGRP antibodies to prevent a reporting bias. These
patients might have been the first to receive the treat-
ment because they were exceptionally severely affected.
Hence, we cannot completely rule out a sampling bias.
Confounding factors, such as concomitant preventive
medication, have not been fully reported but are
expected to be in a very low range. Nevertheless, we
cannot exclude that additional migraine prophylaxis
had an influence on the data.
In addition, the collected data does not allow veri-
fying that all patients had been treatment responders
after six treatment months. Nevertheless, we assume
that all participating neurologists would have inter-
rupted the treatment had patients been non-responders.
Finally, the sample size was rather small; hence, gen-
eralisability may be limited.
Conclusion
Only a small proportion of the therapeutic effect of
anti-CGRP antibodies outlasts their pharmacological
effect. In our sample, migraine frequency rose in
most patients after treatment interruption, and usually,
prophylaxis was required again soon.
It is reasonable to limit prophylactic treatment to
those who benefit and to confirm the need for prophy-
laxis periodically. However, our data do not support
the need for prescheduled treatment discontinuation
after 12 months and a fixed duration of the treatment
interruption of 3 months.
Clinical implications
• After the interruption of the treatment with antibodies directed against CGRP or its receptors, migraine
frequency rises quickly in most patients, and prophylaxis was usually required again soon.
• In the third month after treatment interruption, migraine frequency had not reached baseline values in
most participants, suggesting that a small portion of the therapeutic effect of anti-CGRP antibodies out-
lasts their pharmacological effect.
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